<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34436783</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission.</ArticleTitle><Pagination><StartPage>205</StartPage><EndPage>210</EndPage><MedlinePgn>205-210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27296</ELocationID><Abstract><AbstractText>The long-term evolution of COVID-19 is unknown, making it necessary to study the persistence of symptoms over time and their impact on quality of life in people who have had the disease. We analyzed these aspects 1 year after admission for COVID-19 and explored the influence of treatment with systemic corticosteroids during the acute phase of the illness. This observational cohort study took place in a tertiary hospital in March and April 2021 and included people admitted due to infection with SARS-CoV-2 in March, April, or May 2020. We excluded patients who had died, were unreachable or had substantial cognitive impairment. A telephone survey was undertaken to assess the presence of symptoms related to COVID-19 and to administer the SF-36 quality of life questionnaire. Other variables collected were demographic and clinical data along with the treatment received and the evolution over time. We analyzed 76 patients, including 44 who did not receive corticosteroids and 32 who did. Most symptoms were less frequent in the group that received corticosteroids, with statistically significant differences for headache, dysphagia, chest pain, and depression. These patients also showed significantly better outcomes in the SF-36 domains for "bodily pain" and "mental health." Corticosteroids administered in the acute phase of COVID-19 could attenuate the presence of long-term symptoms and improve patients' quality of life.</AbstractText><CopyrightInformation>&#xa9; 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Catal&#xe1;n</LastName><ForeName>Ignacio P&#xe9;rez</ForeName><Initials>IP</Initials><Identifier Source="ORCID">0000-0002-2146-378X</Identifier><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;</LastName><ForeName>Celia Roig</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sota</LastName><ForeName>Daniela Palomo de la</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvarez</LastName><ForeName>Alejandro Cardenal</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gimeno</LastName><ForeName>Maria Jos&#xe9; Esteve</ForeName><Initials>MJE</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juana</LastName><ForeName>Sergio Fabra</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Germ&#xe1;n Herrero</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajo</LastName><ForeName>Elena Dom&#xed;nguez</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaya</LastName><ForeName>Nuria Tornador</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>Jorge Us&#xf3;</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinc&#xf3;n</LastName><ForeName>Jose Manuel Ramos</ForeName><Initials>JMR</Initials><AffiliationInfo><Affiliation>Internal Medicine Service, University General Hospital of Alicante, Alicante, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>12</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34436783</ArticleId><ArticleId IdType="pmc">PMC8662039</ArticleId><ArticleId IdType="doi">10.1002/jmv.27296</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Ministerio de Sanidad
. consumo y bienestar social; 2021. Accessed April 27, 2021. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/situacionActual.html
</Citation></Reference><Reference><Citation>
Johns Hopkins Coronavirus Resource Center
. Accessed April 27, 2021. https://coronavirus.jhu.edu/map.html
</Citation></Reference><Reference><Citation>Menni C, Valdes AM, Freidin MB, et al. Real&#x2010;time tracking of self&#x2010;reported symptoms to predict potential COVID&#x2010;19. Nat Med. 2020;26(7):1037&#x2010;1040. 10.1038/s41591-020-0916-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0916-2</ArticleId><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration, UK. COVID&#x2010;19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033&#x2010;1034. 10.1016/S0140-6736(20)30628-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID&#x2010;19): a review. JAMA. 2020;324(8):782&#x2010;793. 10.1001/jama.2020.12839</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia&#x2010;Vidal C, Moreno&#x2010;Garc&#xed;a E, Hern&#xe1;ndez&#x2010;Meneses M, et al. Personalized therapy approach for hospitalized patients with COVID&#x2010;19. Clin Infect Dis. 2020:ciaa964. 10.1093/cid/ciaa964</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa964</ArticleId><ArticleId IdType="pmc">PMC7454444</ArticleId><ArticleId IdType="pubmed">32649747</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Lim WS, et al, RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with Covid&#x2010;19. N Engl J Med. 2021;384(8):693&#x2010;704. 10.1056/NEJMoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID&#x2010;19 rapid guideline : managing the long&#x2010;term effects of COVID&#x2010;19. London: National Institute for Health and Care Excellence (UK); 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>
Brito&#x2010;Zer&#xf3;n P, Conangla L, Kostov B, et al. Manifestaciones persistentes de la COVID&#x2010;19. Gu&#xed;a de pr&#xe1;ctica cl&#xed;nica [Internet]. 1st ed. Barcelona: Sociedad Catalana de Medicina Familiar i Comunit&#xe0;ria (CAMFiC), 2020. 1&#x2013;43. Accessed April 27, 2021. https://www.semfyc.es/formaciony-recursos/manifestaciones-persistentes-de-la-covid-19-guia-depractica-clinica/
</Citation></Reference><Reference><Citation>Ware JE Jr., Sherbourne CD. The MOS 36&#x2010;item short&#x2010;form health survey (SF&#x2010;36). I. Conceptual framework and item selection. Med Care. 1992;30:473&#x2010;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty&#x2010;day outcomes among patients hospitalized with COVID&#x2010;19. Ann Intern Med. 2021;174(4):576&#x2010;578. 10.7326/M20-5661</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5661</ArticleId><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xu H, Jiang H, et al. Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study. QJM. 2020;113(9):657&#x2010;665. 10.1093/qjmed/hcaa178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcaa178</ArticleId><ArticleId IdType="pmc">PMC7313792</ArticleId><ArticleId IdType="pubmed">32442308</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID&#x2010;19 infection: a cross&#x2010;sectional evaluation. J Med Virol. 2021;93(2):1013&#x2010;1022. 10.1002/jmv.26368</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli against COVID&#x2010;19 Post&#x2010;Acute Care Study Group. Persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324(6):603&#x2010;605. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno&#x2010;P&#xe9;rez O, Merino E, Leon&#x2010;Ramirez JM, et al, COVID19&#x2010;ALC research group. Post&#x2010;acute COVID&#x2010;19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378&#x2010;383. 10.1016/j.jinf.2021.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>